Susquehanna International Group
CBAY

Susquehanna International Group’s Cymabay Therapeutics CBAY Stock Holding History

Susquehanna International Group’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-783,900
Closed -$18.5M – 13723
2023
Q4 		$18.5M Buy
783,900
+590,600
+306% +$10.5M ﹤0.01% 1898
2023
Q3 		$2.88M Buy
193,300
+79,700
+70% +$1.06M ﹤0.01% 4453
2023
Q2 		$1.24M Sell
113,600
-64,400
-36% -$600K ﹤0.01% 6192
2023
Q1 		$1.55M Buy
178,000
+78,800
+79% +$631K ﹤0.01% 5721
2022
Q4 		$622K Buy
99,200
+40,400
+69% +$154K ﹤0.01% 7305
2022
Q3 		$206K Sell
58,800
-18,900
-24% -$67.9K ﹤0.01% 10760
2022
Q2 		$229K Sell
77,700
-32,800
-30% -$78.3K ﹤0.01% 10291
2022
Q1 		$344K Sell
110,500
-85,100
-44% -$268K ﹤0.01% 9927
2021
Q4 		$661K Buy
195,600
+9,600
+5% +$36.4K ﹤0.01% 8416
2021
Q3 		$679K Buy
186,000
+17,100
+10% +$67.4K ﹤0.01% 8610
2021
Q2 		$736K Buy
168,900
+55,800
+49% +$247K ﹤0.01% 8616
2021
Q1 		$513K Sell
113,100
-75,300
-40% -$405K ﹤0.01% 9407
2020
Q4 		$1.08M Sell
188,400
-154,300
-45% -$1.17M ﹤0.01% 6536
2020
Q3 		$2.48M Buy
342,700
+122,400
+56% +$654K ﹤0.01% 4212
2020
Q2 		$769K Buy
+220,300
New +$636K ﹤0.01% 6472
2020
Q1 		– Sell
-46,300
Closed -$91K – 11061
2019
Q4 		$91K Sell
46,300
-465,100
-91% -$1.75M ﹤0.01% 9179
2019
Q3 		$2.62M Buy
511,400
+63,100
+14% +$382K ﹤0.01% 3722
2019
Q2 		$3.21M Buy
448,300
+382,000
+576% +$4.33M ﹤0.01% 3343
2019
Q1 		$880K Buy
66,300
+40,000
+152% +$425K ﹤0.01% 5266
2018
Q4 		$207K Sell
26,300
-2,200
-8% -$20.9K ﹤0.01% 7678
2018
Q3 		$316K Sell
28,500
-13,000
-31% -$161K ﹤0.01% 7389
2018
Q2 		$557K Sell
41,500
-73,400
-64% -$919K ﹤0.01% 6576
2018
Q1 		$1.49M Buy
114,900
+100,800
+715% +$1.25M ﹤0.01% 4460
2017
Q4 		$130K Sell
14,100
-12,600
-47% -$108K ﹤0.01% 8581
2017
Q3 		$215K Buy
+26,700
New +$181K ﹤0.01% 7908

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Susquehanna International Group's CBAY Position: Q1 2024 in Review

Susquehanna International Group sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 68,457 shares — an estimated $1.62M sold.

Susquehanna International Group first reported a position in CBAY in Q1 2015 and held it in 22 quarters. The position peaked at $10.3M in Q1 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Susquehanna International Group reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Susquehanna International Group sold 68,457 Cymabay Therapeutics shares in Q1 2024, an estimated $1.62M.
  • Susquehanna International Group first reported a position in Cymabay Therapeutics in Q1 2015 and held it in 22 quarters.
  • Susquehanna International Group's Cymabay Therapeutics position peaked at $10.3M in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.